Welcome to our dedicated page for AC Immune news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune stock.
AC Immune SA (ACIU) is a Swiss clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases like Alzheimer's. This page provides investors and researchers with centralized access to official news, financial disclosures, and scientific developments directly from the company.
Key resources include earnings reports, clinical trial updates, strategic collaborations, and regulatory milestones. Stay informed on ACIU's progress in developing diagnostic tools and therapies targeting protein misfolding pathologies through its proprietary platforms.
Content spans pipeline advancements, peer-reviewed research highlights, and material business events. Bookmark this page to efficiently track ACIU's contributions to neuroscience innovation and make data-driven decisions based on verified company communications.
AC Immune (NASDAQ: ACIU) has reported positive interim results from its Phase 2 VacSYn clinical trial of ACI-7104.056, an active immunotherapy for early Parkinson's disease. The treatment has demonstrated significant efficacy, producing anti-α-synuclein antibody levels over 20-fold higher than placebo after 4 immunizations.
The trial's Part 1 involves over 30 patients randomized at a 3:1 ratio (treatment:placebo). Key findings show that antibody responses were effectively induced at week 6 after 2 immunizations and were further enhanced with additional doses. The treatment has shown a favorable safety profile with no serious adverse events reported, with only mild side effects including injection site reactions and headaches.
Based on upcoming interim results in 2025, including pharmacodynamic and biomarker data, the company may proceed with Part 2 of the trial, expanding to up to 150 patients. This phase will evaluate disease progression through motor and non-motor symptoms, along with digital, imaging, and fluid biomarkers.
AC Immune (NASDAQ: ACIU) has announced multiple presentations at the upcoming International Conference on Alzheimer's and Parkinson's Disease (AD/PD™ 2025) in Vienna, Austria, from April 1-5, 2025. The company will host an industry symposium on April 2, focusing on active immunotherapies for neurodegenerative diseases.
The symposium will feature presentations on:
- Disease modification in Parkinson's disease
- ACI-7104.056 Phase 2 trial VacSYn
- ACI-35.030/JNJ2056 Phase 2b Retain study
- ACI-24.060 Phase 1b/2 ABATE study
Additional oral presentations will cover Morphomer® small molecules targeting Tau, Morphomer-antibody drug conjugates, and therapeutic molecules targeting alpha-synuclein aggregation. The event will include presentations from AC Immune leadership, key opinion leaders, and collaboration partners from Johnson & Johnson Innovative Medicine.
AC Immune (NASDAQ: ACIU) reported its full year 2024 financial results, highlighting a landmark deal with Takeda worth $100 million upfront and potential milestones up to $2.1 billion plus royalties for ACI-24.060. The company received a CHF 24.6 million milestone payment from Janssen for enrollment progress in the JNJ-2056 Phase 2b trial.
Key financial metrics include:
- Cash position of CHF 165.5 million, providing funding into Q1 2027
- Contract revenues of CHF 27.3 million in 2024
- R&D expenses increased to CHF 62.6 million
- Net loss of CHF 50.9 million
Clinical progress includes positive interim safety data for ACI-24.060 in Down syndrome patients and encouraging results for ACI-7104.056 in Parkinson's disease. The company expects 2025 total cash expenditure between CHF 75-85 million.
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases, has announced its participation in two major investor conferences in March 2025:
- Leerink Partners 2025 Global Healthcare Conference - Management will hold investor meetings on March 10, 2025
- Barclays 27th Annual Global Healthcare Conference - Management will conduct investor meetings on March 11, 2025
Interested parties can arrange one-on-one meetings with AC Immune's management team through their Leerink or Barclays representatives or by contacting AC Immune directly.
AC Immune announced interim safety data from the Phase 1b/2 ABATE trial of ACI-24.060 in individuals with Down syndrome (DS). The trial evaluates an active immunotherapy targeting toxic forms of amyloid beta. Key findings from the first two cohorts receiving low and mid-dose treatments showed:
- No serious adverse events related to the study drug
- No cases of amyloid-related imaging abnormalities (ARIA)
- Subjects treated for up to one year
Based on these encouraging results, AC Immune plans to proceed with the high-dose cohort. The ABATE study is ongoing at sites in the U.S., U.K., and Spain. ACI-24.060 has received Fast Track designation from the FDA for Alzheimer's disease treatment.
AC Immune (NASDAQ: ACIU) announced positive interim results from its Phase 2 VacSYn trial of ACI-7104.056, an active immunotherapy for early Parkinson's disease. The treatment showed significant efficacy, inducing anti-a-synuclein antibody levels 16-fold higher than placebo after 3 immunizations, with a 100% patient response rate. The trial reported positive safety data with only minor side effects including injection site reactions (49%) and headaches (18%). The study may expand to Part 2 with up to 150 patients in H1 2025, focusing on motor symptoms and biomarkers for potential pivotal study transition.
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company focused on neurodegenerative diseases, has announced its participation in the Jefferies 2024 London Healthcare Conference. The company will engage in a fireside chat on November 20, 2024, at 6:00 AM (ET) / 11:00 AM (GMT), along with one-on-one investor meetings during the conference scheduled for November 19-21, 2024. The event will be held in-person in London, with a webcast available on AC Immune's website Events Page, including a replay option for later viewing.
AC Immune (NASDAQ: ACIU) reported Q3 2024 financial results with a net income of CHF 5.5 million, compared to a net loss of CHF 15.1 million in Q3 2023. Contract revenues reached CHF 25.5 million, primarily from a CHF 24.6 million milestone payment from Janssen. The company ended Q3 with CHF 157.9 million in cash, providing runway into 2027.
Key developments include Fast Track designation from FDA for JNJ-2056 in Alzheimer's disease and progress in the Phase 2 VacSYn trial for Parkinson's disease. R&D expenses increased to CHF 14.5 million from CHF 12.4 million year-over-year, while G&A expenses rose slightly to CHF 3.8 million.
AC Immune SA (NASDAQ: ACIU) has received a second milestone payment of CHF 24.6 million from Janssen Pharmaceuticals for the rapid prescreening rate in the Phase 2b ReTain trial of ACI-35.030 (JNJ-2056) for preclinical Alzheimer's disease. This brings the total milestone payments for this trial to CHF 40 million. The potentially registrational trial aims to enroll about 500 participants with pre-symptomatic AD.
Key points:
- JNJ-2056 received FDA Fast Track designation in July 2024
- AC Immune has received approximately CHF 425 million in milestone and upfront payments from collaborations
- The company has a three-year cash runway
- ACI-35.030 targets pathological phosphorylated-Tau protein (pTau)
- The trial is the first to test an active immunotherapy in preclinical AD population
AC Immune's partner, Life Molecular Imaging (LMI), has received Fast Track Designation from the FDA for the Tau-PET diagnostic [18F]PI-2620 in three neurodegenerative conditions: Alzheimer's disease (AD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). PI-2620, currently in Phase 3 clinical development for detecting Tau pathology in AD, is a next-generation PET imaging agent. This designation aims to accelerate development and review, highlighting the importance of early and accurate diagnoses in neurodegenerative diseases.
The Fast Track status for PI-2620 follows similar designations for AC Immune's active immunotherapies ACI-35.030 and ACI-24.060, both in Phase 2. This recognition underscores AC Immune's leadership in developing precision therapeutics for neurodegenerative diseases and its commitment to improving patient care through early diagnosis and treatment.
